AAPL   264.51 (-3.29%)
FB   185.85 (-2.06%)
MSFT   156.71 (-0.93%)
AMZN   1,835.94 (-2.57%)
CGC   17.88 (-3.04%)
BABA   200.25 (-2.33%)
TSLA   631.00 (-7.07%)
AMD   42.90 (-2.52%)
T   34.25 (-4.14%)
ACB   1.34 (-7.58%)
F   6.77 (-3.01%)
BAC   27.85 (-4.39%)
GILD   67.79 (-6.70%)
DIS   114.31 (-3.16%)
AAPL   264.51 (-3.29%)
FB   185.85 (-2.06%)
MSFT   156.71 (-0.93%)
AMZN   1,835.94 (-2.57%)
CGC   17.88 (-3.04%)
BABA   200.25 (-2.33%)
TSLA   631.00 (-7.07%)
AMD   42.90 (-2.52%)
T   34.25 (-4.14%)
ACB   1.34 (-7.58%)
F   6.77 (-3.01%)
BAC   27.85 (-4.39%)
GILD   67.79 (-6.70%)
DIS   114.31 (-3.16%)
AAPL   264.51 (-3.29%)
FB   185.85 (-2.06%)
MSFT   156.71 (-0.93%)
AMZN   1,835.94 (-2.57%)
CGC   17.88 (-3.04%)
BABA   200.25 (-2.33%)
TSLA   631.00 (-7.07%)
AMD   42.90 (-2.52%)
T   34.25 (-4.14%)
ACB   1.34 (-7.58%)
F   6.77 (-3.01%)
BAC   27.85 (-4.39%)
GILD   67.79 (-6.70%)
DIS   114.31 (-3.16%)
AAPL   264.51 (-3.29%)
FB   185.85 (-2.06%)
MSFT   156.71 (-0.93%)
AMZN   1,835.94 (-2.57%)
CGC   17.88 (-3.04%)
BABA   200.25 (-2.33%)
TSLA   631.00 (-7.07%)
AMD   42.90 (-2.52%)
T   34.25 (-4.14%)
ACB   1.34 (-7.58%)
F   6.77 (-3.01%)
BAC   27.85 (-4.39%)
GILD   67.79 (-6.70%)
DIS   114.31 (-3.16%)
Log in

NASDAQ:VSTM - Verastem Stock Price, Forecast & News

$2.36
+0.45 (+23.56 %)
(As of 02/28/2020 10:56 AM ET)
Today's Range
$2.13
Now: $2.36
$2.59
50-Day Range
$1.72
MA: $1.96
$2.18
52-Week Range
$0.83
Now: $2.36
$3.66
Volume5.08 million shs
Average Volume1.65 million shs
Market Capitalization$175.47 million
P/E RatioN/A
Dividend YieldN/A
Beta2.85
Verastem, Inc, a biopharmaceutical company, focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:VSTM
CUSIP92337C10
Phone781-292-4200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$26.72 million
Book Value$1.68 per share

Profitability

Net Income$-72,430,000.00
Net Margins-809.25%

Miscellaneous

Employees169
Market Cap$175.47 million
Next Earnings Date3/10/2020 (Estimated)
OptionableOptionable

Receive VSTM News and Ratings via Email

Sign-up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter.


Verastem (NASDAQ:VSTM) Frequently Asked Questions

What is Verastem's stock symbol?

Verastem trades on the NASDAQ under the ticker symbol "VSTM."

How were Verastem's earnings last quarter?

Verastem Inc (NASDAQ:VSTM) issued its earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping the Zacks' consensus estimate of ($0.43) by $0.14. The biopharmaceutical company had revenue of $15.51 million for the quarter. Verastem had a negative net margin of 809.25% and a negative return on equity of 160.88%. View Verastem's Earnings History.

When is Verastem's next earnings date?

Verastem is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Verastem.

What price target have analysts set for VSTM?

6 brokers have issued 12-month price targets for Verastem's stock. Their forecasts range from $2.50 to $9.00. On average, they expect Verastem's stock price to reach $5.75 in the next twelve months. This suggests a possible upside of 153.3% from the stock's current price. View Analyst Price Targets for Verastem.

What is the consensus analysts' recommendation for Verastem?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verastem in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Verastem.

Has Verastem been receiving favorable news coverage?

Media coverage about VSTM stock has trended very negative recently, InfoTrie reports. InfoTrie scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Verastem earned a media sentiment score of -3.5 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the immediate future. View News Stories for Verastem.

Are investors shorting Verastem?

Verastem saw a increase in short interest in the month of February. As of February 14th, there was short interest totalling 13,400,000 shares, an increase of 17.0% from the January 30th total of 11,450,000 shares. Based on an average trading volume of 2,550,000 shares, the short-interest ratio is currently 5.3 days. Currently, 19.7% of the shares of the stock are sold short. View Verastem's Current Options Chain.

Who are some of Verastem's key competitors?

What other stocks do shareholders of Verastem own?

Who are Verastem's key executives?

Verastem's management team includes the folowing people:
  • Mr. Robert Forrester, Pres, CEO & Director (Age 55)
  • Mr. Robert E. Gagnon, Chief Financial Officer (Age 45)
  • Mr. Joseph M. Lobacki, Exec. VP & Chief Commercial Officer (Age 61)
  • Mr. Richard H. Aldrich M.B.A., Mba, Founder and Consultant (Age 65)
  • Dr. Robert A. Weinberg, Co-Founder and Chair of Scientific Advisory Board

Who are Verastem's major shareholders?

Verastem's stock is owned by many different of institutional and retail investors. Top institutional investors include Stifel Financial Corp (0.36%), Howland Capital Management LLC (0.20%), UBS Group AG (0.17%), Creative Planning (0.16%), Renaissance Technologies LLC (0.13%) and Samalin Investment Counsel LLC (0.12%). Company insiders that own Verastem stock include Dan Paterson, Joseph M Lobacki, Michael Kauffman, Robert Forrester, Steven H Bloom and Timothy J Barberich. View Institutional Ownership Trends for Verastem.

Which major investors are selling Verastem stock?

VSTM stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Howland Capital Management LLC, Stifel Financial Corp and UBS Group AG. View Insider Buying and Selling for Verastem.

Which major investors are buying Verastem stock?

VSTM stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Samalin Investment Counsel LLC, Oxford Asset Management LLP, Middleton & Co Inc MA, Creative Planning, National Asset Management Inc., Aries Wealth Management and Raymond James Financial Services Advisors Inc.. Company insiders that have bought Verastem stock in the last two years include Dan Paterson, Joseph M Lobacki, Michael Kauffman, Robert Forrester, Steven H Bloom and Timothy J Barberich. View Insider Buying and Selling for Verastem.

How do I buy shares of Verastem?

Shares of VSTM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Verastem's stock price today?

One share of VSTM stock can currently be purchased for approximately $2.27.

How big of a company is Verastem?

Verastem has a market capitalization of $168.77 million and generates $26.72 million in revenue each year. The biopharmaceutical company earns $-72,430,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis. Verastem employs 169 workers across the globe.View Additional Information About Verastem.

What is Verastem's official website?

The official website for Verastem is http://www.verastem.com/.

How can I contact Verastem?

Verastem's mailing address is 117 KENDRICK STREET SUITE 500, NEEDHAM MA, 02494. The biopharmaceutical company can be reached via phone at 781-292-4200 or via email at [email protected]


MarketBeat Community Rating for Verastem (NASDAQ VSTM)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  523 (Vote Outperform)
Underperform Votes:  486 (Vote Underperform)
Total Votes:  1,009
MarketBeat's community ratings are surveys of what our community members think about Verastem and other stocks. Vote "Outperform" if you believe VSTM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VSTM will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel